News
Camurus AB (CAMRF) reports a 52% revenue increase, strategic licensing with Eli Lilly, and EU approval of Oczyesa, despite currency challenges and market hurdles.
Find the latest Camurus AB (publ) (CAMRF) stock quote, history, news and other vital information to help you with your stock trading and investing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback